EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022

Bourama Traoré, Merepen A Guindo, Drissa Konaté, Fousseyni Kané, Nathan C Incandela, Abdouramane Traore, Salimata Kanté, Mariam Sidibé, Bourama Keita, Fatoumata Kasse, Karamoko Tangara, Dramane Diallo und 14 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Bourama Traoré und 25 weiteren Autor:innen. Beteiligte Einrichtung: International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPHA), University Cli…. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WHO/Afro, WHO Unity Studies, FIC NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The sero‐epidemiological characteristics of SARS‐CoV‐2 infections in Mali are not yet well understood. This study assessed SARS‐CoV‐2 antibody seroprevalence and factors associated with antibody responses in the general population of Bamako, the capital city and epicenter of COVID‐19, to assess the magnitude of the pandemic and contribute to control strategy improvements in Mali.

Methods

A cross‐sectional survey was conducted in September 2022 to collect sociodemographic information, clinical characteristics, comorbid factors, and blood samples. ELISA was performed to determine anti‐Spike (anti‐S) and anti‐RBD antibody levels. A total of 3601 participants were enrolled in REDCap. R‐Studio was used for the statistical analysis. The chi‐squared (χ 2 ) test was used to compare the proportions across different groups. Logistic regression models were used to elucidate factors associated with antibody responses.

Result

The sex ratio for female‐to‐male was 3.6:1. The most representative groups were the 20–29‐year‐olds (28.9%, n = 1043) and the 30–39‐year‐olds (26.9%, n = 967). The COVID‐19 vaccine coverage among the participants was 35.8%, with vaccines from Covishield AstraZeneca (13.4%), Johnson & Johnson (16.7%), Sinovac (3.9%), and BioNTech Pfizer (1.8%). Overall, S protein and RBD antibody seroprevalences were remarkably high in the study population (98% and 97%, respectively). Factors such as youth (1–9 years old) and male sex were associated with lower SARS‐CoV‐2 antibody responses, whereas COVID‐19 vaccinations were associated with increased antibody responses.

Conclusion

This serosurvey demonstrated the high seroprevalence of SARS‐CoV‐2 antibodies and highlighted the factors influencing antibody responses, while clearly underlining an underestimation of the pandemic in Mali.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralSARS-CoV-2HumansMaliSeroepidemiologic StudiesMaleFemaleCross-Sectional StudiesAdultMiddle AgedYoung AdultAdolescentChildAgedChild, PreschoolSpike Glycoprotein, CoronavirusInfant

Stichwörter der Autor:innen

BamakoMaliSARS‐CoV‐2 antibodiesassociated factorsseroprevalence

Substanzen

Antibodies, ViralSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • International Center for Excellence in Research (ICER), Faculty of Medicine and Odontostomatology (FMOS), Faculty of Pharmacy (FAPHA), University Clinical Research Center (UCRC) at the University of Sciences, Techniques…
  • Center for Polymers and Organic Solids, Department of Chemistry and Biochemistry, University of California Santa Barbara, Santa Barbara, California, USA.
  • District Health Center of Commune 4 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
  • Hospital District Health of Commune 1 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
  • District Health Center of Commune 6 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.
  • District Health Center of Commune 5 of Bamako, Minister of Health and Social Development of Mali, Bamako, Mali.

ORCID-Profile: Saidou Balam

Förderung

  • WHO/Afro
  • WHO Unity Studies
  • FIC NIH HHS
  • German Federal Ministry of Health
  • COVID-19 Solidarity Response Fund

Zitieren

APA

Traoré, B., Guindo, M. A., Konaté, D., Kané, F., Incandela, N. C., Traore, A., Kanté, S., Sidibé, M., Keita, B., Kasse, F., Tangara, K., Diallo, D., Maiga, I. Y., Thiam, S., Cisse, A., Siby, K. M., Dicko, A. R., Goita, M., Kone, D., …, & Balam, S. (2024). Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13343

Vancouver

Traoré B, Guindo MA, Konaté D, Kané F, Incandela NC, Traore A, et al. Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13343

BibTeX
@article{Traor2024,
  author = {Traoré, Bourama and Guindo, Merepen A and Konaté, Drissa and Kané, Fousseyni and Incandela, Nathan C and Traore, Abdouramane and Kanté, Salimata and Sidibé, Mariam and Keita, Bourama and Kasse, Fatoumata and Tangara, Karamoko and Diallo, Dramane and Maiga, Issoufi Y and Thiam, Salif and Cisse, Abdourhamane and Siby, Khatry M and Dicko, Abdoul R and Goita, Mariam and Kone, Diakaridia and Diallo, Mamadou and Traore, Modibo and Coulibaly, Yaya I and Diakité, Mahamadou and Doumbia, Seydou and Dolo, Housseini and Balam, Saidou},
  title = {Seroprevalence of SARS‐CoV‐2 Antibodies and Associated Factors in Bamako, Mali: A Population‐Based Cross‐Sectional Study in September 2022},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13343}
}
Kostenlos starten →